To successfully commercialize orphan drugs, companies need to set aside general medicine strategies and adopt a more granular approach to identifying and capitalizing on commercial opportunities.
Dennis Fournogerakis
Advertisement
Dennis Fournogerakis is an associate partner at Beghou Consulting.
Articles by Dennis Fournogerakis
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Bayer’s Lynkuet as First Dual Neurokinin Antagonist for Menopausal Hot Flashes
2
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
3
Lilly Enters Definitive Agreement Acquiring Aderum Biotechnologies
4
Could DTC Programs Help Simplify the Drug-Pricing System?
5
